Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05736549

Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2

Led by Yale University · Updated on 2025-05-14

66

Participants Needed

2

Research Sites

264 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

D

Department of Anesthesiology Faculty Development Fund

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this study is to investigate the efficacy of Dexamethasone sodium phosphate plus Methylprednisolone acetate in combination with plain bupivacaine ((B-DEX-MPA) compared with Liposomal Bupivacaine in combination with plain bupivacaine (B-LB) on post-surgical pain control among patients undergoing bilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.

CONDITIONS

Official Title

Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Elective, primary, bilateral total knee arthroplasty planned with spinal anesthesia using plain 0.5% bupivacaine
  • American Society of Anesthesiologists status I, II, or III
Not Eligible

You will not qualify if you...

  • Refusal to consent to participate
  • Pregnancy
  • Unable to complete follow-up questionnaires online, by email, or phone due to cognitive dysfunction, psychiatric disorder, non-English speaking, or lack of internet access
  • Coagulopathy
  • Allergy or contraindication to acetaminophen, Celebrex, bupivacaine, dexamethasone, methylprednisolone acetate, or liposomal bupivacaine
  • Opioid use within one month before surgery or regular marijuana use more than once per month
  • Insulin dependent or uncontrolled diabetes (surgery day glucose >200mg/dl or HbA1C > 8.0%)
  • Infection at peripheral nerve block site or systemic infection
  • Immune compromise such as HIV or chronic glucocorticoid use
  • Severe pre-existing neuropathy
  • TKA for reasons other than osteoarthritis, history of surgery in the same knee, revision TKA, or bilateral TKA
  • Severe liver or kidney dysfunction (GFR <50 ml/min)
  • Body weight less than 60 kg
  • Active or latent peptic ulcers, diverticulitis, recent intestinal surgery, or non-specific ulcerative colitis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Yale New Haven Hospital Saint Raphael Campus

New Haven, Connecticut, United States, 06520

Actively Recruiting

2

Yale New Haven Hospital York Street Campus

New Haven, Connecticut, United States, 06520

Actively Recruiting

Loading map...

Research Team

J

Jinlei Li, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2 | DecenTrialz